Initiative Increased BRCA Testing in Ovarian Cancer Patients
A multipronged initiative increased germline BRCA mutation testing for patients with ovarian cancer by 31%.
A multipronged initiative increased germline BRCA mutation testing for patients with ovarian cancer by 31%.
A presentation at the 2023 ONA Summit reviewed diagnosis and treatment recommendations for uterine, ovarian, and endometrial cancers.
Study shows that polygenic score does not modify the 13 percent reduction in ovarian cancer risk seen with aspirin.
Individual lifetime ovulatory years components associated with epithelial ovarian cancer apart from age at menarche.
Mirvetuximab soravtansine has shown activity in a phase 2 trial of biomarker-selected patients with platinum-resistant ovarian cancer.
The consumption of ultra-processed foods is associated with an increased risk of developing cancer and dying from it, a large study suggests.
An experimental analysis sought to determine the usefulness of a natural language processing approach to measure openness of communication about genetic risk within families with hereditary breast and ovarian cancer syndrome.
Researchers sought to determine whether survivors of gynecologic cancers had a higher risk of sexual dysfunction, compared with cancer-free women, and the risk factors for sexual dysfunction.
The decision to restrict the indication follows an FDA review of the double-blind, placebo-controlled phase 3 ENGOT-OV16/NOVA trial.
The approval was based on data from the SORAYA trial.